Group 1 - Humana Inc. is a significant player in the S&P 500, recently highlighted for its exposure to Medicare Advantage, which has led to a notable sell-off in its stock [1] - The company was the third worst performer in the S&P last month, primarily due to the announcement from the Centers for Medicare & Medicaid Services that payments to private insurers would remain nearly flat, contrary to Wall Street's expectation of a 5% increase [1] - Humana provides various medical insurance plans, prescription drug programs, and operates its own network of primary care centers and home health services [3] Group 2 - The investment community acknowledges both the risks and potential of Humana, but there is a belief that certain AI stocks may offer greater returns in a shorter time frame compared to Humana [4]

Company Overview - Oscar Health, Inc. (NYSE:OSCR) provides medical insurance plans for individuals, families, and small businesses [2] Recent Performance - Oscar Health reversed from being a contributor to a detractor in the third quarter of 2025, with claims losses being much worse than expected in the first half of the year [2] - The stock price exceeded $20 per share at the end of the second quarter, but July was a challenging month for Oscar and its industry [2] - As the stock recovered later in the quarter, the Longleaf Partners Small-Cap Fund sold the rest of its position, indicating a successful overall investment despite the volatility [2] Market Sentiment - Jim Cramer expressed a positive sentiment towards Oscar Health, indicating that the leadership of Bertolini is a significant factor in his bullish outlook [1] - There is a belief that certain AI stocks may offer greater upside potential compared to Oscar Health, suggesting a competitive landscape for investment opportunities [3]